Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study)-Reference-Cited by-同舟云学术

Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B: A multicenter randomized trial (ARES study)

Published:2015-02-27 Issue:5 Volume:61 Page:1512-1522
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Brouwer Willem Pieter¹,Xie Qing²,Sonneveld Milan J.¹,Zhang Ningping³,Zhang Qin⁴,Tabak Fehmi⁵,Streinu-Cercel Adrian⁶,Wang Ji-Yao³,Idilman Ramazan⁷,Reesink Hendrik W.⁸,Diculescu Mircea⁹,Simon Krzysztof¹⁰,Voiculescu Mihai¹¹,Akdogan Meral¹²,Mazur Wlodzimierz¹³,Reijnders Jurrien G.P.¹,Verhey Elke¹,Hansen Bettina E.¹¹⁴,Janssen Harry L.A.¹¹⁵,

Affiliation:

1. Department of Gastroenterology and Hepatology; Erasmus MC University Medical Center; Rotterdam The Netherlands

2. Infectious Diseases; Ruijin Hospital, Jiaotong University; Shanghai China

3. Gastroenterology and Hepatology; Zhong Shan Hospital, Fu Dan University; Shanghai China

4. Gastroenterology and Hepatology, Shanghai Public Health Center; Fu Dan University; Shanghai China

5. Cerrahpasa Medical Faculty; Istanbul Turkey

6. National Institute of Infectious Disease; Bucharest Romania

7. University of Ankara, Medical School; Ankara Turkey

8. Department of Gastroenterology and Hepatology; Academic Medical Center; Amsterdam The Netherlands

9. Department of Gastroenterology; Fundeni Cinical Institute; Bucharest Romania

10. Division of Infectious Diseases and Hepatology; Wroclaw Medical University; Wroclaw Poland

11. Department of Internal Medicine; Fundeni Cinical Institute; Bucharest Romania

12. Department of Gastroenterology; Yuksek Ihsitas Hospital; Ankara Turkey

13. Department of Infectious Diseases; Silesian Medical University; Katowice Poland

14. Department of Public Health; Erasmus MC University Medical Center; Rotterdam The Netherlands

15. Toronto Center for Liver Disease; Toronto Western and General Hospital, University Health Network; Toronto Ontario Canada

Funder

Bristol-Myers Squibb

Roche

Netherlands Genomics Initiative

Virgo consortium

Publisher

Wiley

Subject

Hepatology

Reference32 articles.

1. Chronic hepatitis B: update 2009;Lok;Hepatology,2009

2. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability;Kim;Gut,2014

3. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy;Werle-Lapostolle;Gastroenterology,2004

4. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B;Chang;Hepatology,2010

5. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B;Chang;Hepatology,2010

Cited by 146 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanism of interferon alpha therapy for chronic hepatitis B and potential approaches to improve its therapeutic efficacy;Antiviral Research;2024-01

2. Predictors of therapeutic response to peginterferon α‑2a and nucleos(t)ide analog combination therapy for HBeAg‑negative chronic hepatitis B: 1‑year follow‑up after treatment;Experimental and Therapeutic Medicine;2023-11-03

3. End-of-treatment HBsAg, HBcrAg and HBV RNA predict the risk of off-treatment ALT flares in chronic hepatitis B patients;Journal of Microbiology, Immunology and Infection;2023-02

4. Bictegravir/Emtricitabine/Tenofovir Alafenomide for the Treatment of HIV/Hepatitis B Virus Co-infection in Patients with Cancer and Transplant Recipients;Infectious Diseases;2023

5. Reduction of Hepatitis B Surface Antigen May Be More Significant in PEGylated Interferon-Alpha Therapy Combined with Nucleotide Analogues than Combined with Nucleoside Analogues in Chronic Hepatitis B Patients: A Propensity Score Matching Study;Canadian Journal of Gastroenterology and Hepatology;2022-12-07